Low-dose ARB treatment might be considered as a neuroprotective treatment after cerebral infarction, and fimasartan is a good candidate for low-dose treatment because it has highly potent affinity for AT1 compared to other ARBs. Here, AGTR1 is linked to cerebral infarction.